What Is Zelsuvmi Used For? ZELSUVMI™ (berdazimer) is a first-in-class topical medication that was approved by the U.S. Food and Drug Administration on January 5, 2024, making it the first new drug for the treatment…
In March 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Rezdiffra (resmetirom), marking a significant milestone as the first approved treatment for nonalcoholic steatohepatitis (NASH), in adults with moderate to advanced…
Tevimbra, known generically as tislelizumab-jsgr, is a humanized IgG4 monoclonal antibody developed by BeiGene. It functions as a PD-1 inhibitor, aiming to enhance the body’s immune response against cancer cells. Approved for various indications, Tevimbra…
Phil GattonePresident and CEO, National Bleeding Disorders Foundation“…. Qfitlia takes a novel approach to providing protection for people living with hemophilia while reducing the frequency of dosing for patients and their families.” Hemophilia is a…
Letybo(letibotulinumtoxinA-wlbg), developed by South Korean biopharmaceutical company Hugel, has recently received FDA approval for the treatment of moderate to severe glabellar lines (frown lines) in adults. Known as Botulax in South Korea, Letybo has been…
Niktimvo (axatilimab-csfr) is a prescription medicine used to treat chronic graft-versus-host disease (cGVHD) if you have received at least 2 prior treatments and they have not worked. Niktimvo works by targeting the drivers of inflammation and fibrosis that…
In a key step forward in the field of rare disease treatment, the U.S. Food and Drug Administration (FDA) has officially approved Miplyffa (generic name: Arimoclomol), developed by Zevra Therapeutics, is intended for the treatment…
Lazcluze is a cancer medicine used to treat adults with advanced non-small cell lung cancer (NSCLC) who have not been treated before. It is used in people whose cancer cells have certain mutations (changes) in…
Blujepa (gepotidacin) FDA approval was granted on March 25, 2025, to GSK GlaxoSmithKline. Its launch date is expected to be the second half of 2025. What Is The Use Of Blujepa? Blujepa (Gepotidacin) is a…
In a landmark decision, the U.S. Food and Drug Administration (FDA) has approved AQNEURSA™ (levacetylleucine), the first stand-alone therapy for treating neurological symptoms of Niemann-Pick disease type C (NPC), a rare and fatal genetic disorder. Developed by IntraBio…
In the world of rare disease therapeutics, Vimseltinib has emerged as a groundbreaking oral kinase inhibitor. This innovative medication is specifically designed for adults with symptomatic tenosynovial giant cell tumor (TGCT) – a rare, non-cancerous but often debilitating condition…
In January 2025, the FDA approved Grafapex™ (treosulfan) in combination with fludarabine as a conditioning regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT). This approval applies to adult and pediatric patients aged one year and…
